Peel Hunt Reiterates Buy Rating for Puretech Health (PRTC)

Puretech Health (LON:PRTC)‘s stock had its “buy” rating reissued by analysts at Peel Hunt in a research report issued on Tuesday, February 20th. They currently have a GBX 313 ($4.32) price objective on the stock. Peel Hunt’s price objective would suggest a potential upside of 93.21% from the stock’s previous close.

A number of other equities analysts have also issued reports on PRTC. Numis Securities upped their target price on Puretech Health from GBX 207 ($2.86) to GBX 233 ($3.22) and gave the company a “buy” rating in a research report on Thursday, November 30th. Jefferies Group restated a “buy” rating on shares of Puretech Health in a research note on Friday, November 17th. N+1 Singer restated a “buy” rating on shares of Puretech Health in a research note on Thursday, November 30th. Finally, Liberum Capital restated a “buy” rating and set a GBX 248 ($3.43) price objective on shares of Puretech Health in a research note on Friday, January 26th. Five analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average price target of GBX 260.20 ($3.59).

Shares of Puretech Health (PRTC) traded up GBX 4 ($0.06) on Tuesday, hitting GBX 162 ($2.24). The company’s stock had a trading volume of 50,255 shares, compared to its average volume of 66,914. Puretech Health has a one year low of GBX 110 ($1.52) and a one year high of GBX 183.50 ($2.54). The firm has a market cap of $383.14 and a price-to-earnings ratio of -852.63.

In other news, insider Robert Langer bought 4,300 shares of the firm’s stock in a transaction that occurred on Tuesday, March 13th. The stock was acquired at an average price of GBX 162 ($2.24) per share, with a total value of £6,966 ($9,624.21).

COPYRIGHT VIOLATION WARNING: “Peel Hunt Reiterates Buy Rating for Puretech Health (PRTC)” was originally published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at

About Puretech Health

PureTech Health plc is a cross-disciplinary healthcare company. The Company operates through two segments: growth stage businesses and project phase businesses. Businesses in the growth stage businesses segment are those whose activities focus on developing products to solve healthcare problems in varied markets.

Analyst Recommendations for Puretech Health (LON:PRTC)

Receive News & Ratings for Puretech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puretech Health and related companies with's FREE daily email newsletter.

Leave a Reply